# IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ONYX THERAPEUTICS, INC.,	)
Plaintiff,	)
v.	) C.A. No. 17-1155-LPS
INNOPHARMA INC.,	)
Defendant	. )
ONYX THERAPEUTICS, INC.,	)
Plaintiff,	)
V.	) C.A. No. 17-1202-LPS
APOTEX INC. and APOTEX CORP.,	)
Defendant	s. )
ONYX THERAPEUTICS, INC.,	)
Plaintiff,	)
v.	) C.A. No. 17-1235-LPS
QILU PHARMA, INC. and QILU PHARMACEUTICAL CO., LTD.,	) ) )
Defendant	<i>)</i> s. )

# STIPULATION AND [PROPOSED] ORDER

WHEREAS, the actions against InnoPharma Inc. (C.A. No. 17-1155-LPS), Apotex Inc. and Apotex Corp. (C.A. No. 17-1202-LPS), and Qilu Pharma, Inc. and Qilu Pharmaceutical Co., Ltd. (C.A. No. 17-1235-LPS) (collectively, "Related Actions") are related to C.A. No. 16-988 (LPS), which is currently pending before this Court;

WHEREAS, plaintiff Onyx Therapeutics, Inc. and defendants InnoPharma Inc., Apotex Inc., Apotex Corp., Qilu Pharma, Inc., and Qilu Pharmaceutical Co., Ltd. (collectively, "the parties") have agreed to consolidation of the Related Actions with C.A. No. 16-988 (LPS) for purposes of discovery, and further agreed to follow the Scheduling Order (D.I. 21) entered in C.A. No. 16-988 (LPS) on April 18, 2017, as amended by the Stipulation and Proposed Order filed by the parties on September 13, 2017, and except that plaintiff Onyx Therapeutics, Inc. shall serve its Infringement Contentions against defendants InnoPharma Inc., Apotex Inc., Apotex Corp., Qilu Pharma, Inc., and Qilu Pharmaceutical Co., Ltd. by October 2, 2017.

IT IS HEREBY STIPULATED AND AGREED by the parties, subject to the approval of the Court, that:

- 1) The Related Actions shall be consolidated with C.A. No. 16-988 (LPS) for purposes of discovery;
- 2) The parties shall follow the Scheduling Order entered in C.A. No. 16-988 (LPS) (D.I. 21, as entered on April 18, 2017), as amended by the Stipulation and Proposed Order filed by the parties on September 13, 2017, and except that plaintiff Onyx Therapeutics, Inc. shall serve its Infringement Contentions against defendants InnoPharma Inc., Apotex Inc., Apotex Corp., Qilu Pharma, Inc., and Qilu Pharmaceutical Co., Ltd. by October 2, 2017;
  - 3) All filings shall be made in the lead case C.A. No. 16-988 (LPS).

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

PHILLIPS GOLDMAN MCLAUGHLIN & HALL, P.A.

#### /S/ MARYELLEN NOREIKA

Jack B. Blumenfeld (#1014) Maryellen Noreika (#3208) 1201 North Market Street P.O. Box 1347 Wilmington, DE 19899 (302) 658-9200 jblumenfeld@mnat.com mnoreika@mnat.com

Attorneys for Plaintiff Onyx Therapeutics, Inc.

/S/ DAVID A. BILSON

John C. Phillips, Jr. (#110) David A. Bilson (#4986) 1200 North Broom Street Wilmington, DE 19806 (302) 655-4200 jcp@pgmhlaw.com dab@pgmhlaw.com

Attorneys for Defendant InnoPharma Inc.

### SMITH, KATZENSTEIN & JENKINS LLP

## /S/ EVE H. ORMEROD

Neal C. Belgam (#2721) Eve H. Ormerod (#5369) 1000 West Street, Suite 1501 Wilmington, DE 19801 302-652-8400 nbelgam@skjlaw.com eormerod@skjlaw.com

Attorneys for Defendants Qilu Pharma, Inc. and Qilu Pharmaceutical Co., Ltd.

COZEN O'CONNOR

#### /S/ JOSEPH J. BELLEW

Joseph J. Bellew (#4816) 1201 North Market Street, Suite 1001 Wilmington, DE 19801 (302) 295-2025 jbellew@cozen.com

Attorneys for Defendants Apotex Inc. and Apotex Corp.

Dated: September 13, 2017

SO ORDERED this \_\_\_\_\_ day of September, 2017.

Chief, United States District Judge